Overview

Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Status:
Active, not recruiting

Trial end date:
2024-01-20

Target enrollment:

Participant gender:

Summary

Dolutegravir (DTG) is an HIV drug in the integrase inhibitor drug class. This study will test the safety of and immune response to DTG in HIV-1 infected infants, children, and adolescents.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Dolutegravir
Integrase Inhibitors